– Introduction –
Biomedicine is undergoing a round of industrial transformation driven by underlying technologies. Cell therapy, gene therapy, core components of medical devices, and blood purification consumables… These once-cutting-edge concepts are gradually becoming clinical and commercial realities, and are currently the most focused areas for capital.
This issue features five high-quality projects, all advanced to the clinical, registration, or IND preparation stages, and are eligible for various collaborations such as investment, licensing, joint development, and industrial implementation.
Below are the details of this issue’s high-quality medical innovation assets:

1. iNKT and CAR-iNKT tumor immunology platforms

The project focuses on iNKT and CAR-iNKT cell therapies, building a layered product portfolio for liver cancer, pancreatic cancer, and other solid tumors, ranging from autologous iNKT to allogeneic iNKT, and then to CAR-iNKT and iPSC-iNKT. Based on iNKT cells possessing both NK and T cell characteristics, recognizing CD1d glycolipid antigens, and possessing natural tissue homing advantages for solid tumors, Pingtai aims to address issues such as insufficient penetration, weak persistence, and tumor microenvironment suppression in solid tumor immunotherapy.
At present, the core product GKL-006 has become the world’s first clinically approved iNKT cell product for liver cancerCompleted IIT Phase I/II and advanced to Phase II registration clinical trials for liver cancer and Phase I/II for pancreatic cancer; Meanwhile, the company has already received CDE approval for five registered clinical trials and accepted two by the CDE, maintaining a leading overall pace in the global iNKT sector. In addition to the autologous product, the allogeneic GKL-006 Allo/RTU has received IND for acute respiratory distress syndrome and solid tumors, and CAR-iNKT and iPSC-iNKT have also entered the preclinical stage.

The value of the project goes beyond a single liver cancer pipeline, but in its expansion from single-cell products to platform-based layouts. Government projects, hospital collaborations, and registered clinical trials are advancing simultaneously, indicating that basic research, clinical resources, and application capabilities have formed a strong closed loop; On the patent side, the company has completed domestic invention patents, PCT, and patents in the United States and Japan, and holds exclusive rights to the iNKT and CAR-iNKT trademarks. Clients and partners include not only oncology hospitals and leading clinical centers, but also industry partners interested in solid tumor cell therapy. Compared to the more crowded CAR-T sector, iNKT is still in the global early window, but the platform has already taken the lead in first-mover positions in registered clinical trials and intellectual property. For investors, this is a tumor immune cell therapy asset with both clinical progress and platform extension. Whether continuing to advance registration, conducting BD collaborations, or bringing in larger pharmaceutical companies for joint development, there is a clear path to value realization.

The platform has already begun extending from autologous therapies toward off-the-shelf and engineering approaches, which will directly affect future costs, accessibility, and commercialization radius. If allogeneic and engineered products continue to advance, this platform has the opportunity to establish an independent pathway in solid tumor immunotherapy distinct from traditional CAR-T.

2. Precision Micro Motors and Opto-Mechanical Module Platform

Project Focusing on precision micro motors, motion control, and opto-mechanical modules, its core value lies in transferring the proven high-precision drive capabilities of consumer electronics to the medical device field, forming a foundational component platform for medical technology. The company has long focused on voice coil motors, piezoelectric ceramic motors, OIS/AF, stabilization modules, liquid lenses, and periscope systems, possessing complete capabilities from design introduction and prototype validation to mass production, and has formed a strong intellectual property barrier. Currently, the company holds 126 patents, including 74 invention patents, of which 40 invention patents have been granted; At the product level, we have mass-produced or advanced a variety of precision components such as spring-type OIS, Piezo IRIS, periscope motors, Piezo OIS, optical AF motors, and modular micro-gimbals. For the medical device industry, the significance of such upstream capabilities lies in the fact that miniaturized, highly stable, and highly consistent micro-driver units often directly determine the sensitivity, portability, and product upgrade potential of end devices.
What deserves more attention for the project is its Design-In capabilities in medical settings, rather than the sales of individual components. The materials clearly list neonatal incubators, CT auxiliary devices, insulin pumps, hemodialysis machines, gene amplification instruments, needle-free injection delivery systems, and biochemical analyzers as application directions, indicating that the platform is extending from standard industrial devices to core medical custom components. The company has 3 R&D centers, 2 production bases, and 5 marketing centers, capable of undertaking the entire process for medical device manufacturers from initial definition, joint development, to subsequent mass supply. For medical device companies, the value of such platforms is not just about purchasing a part, but about obtaining sustainable, iterated precision execution solutions; For investors, this corresponds to a business model of “key components entering terminal devices and forming long-term supply.” Once more implementation validation is completed on the medical device side, the platform has the opportunity to become an irreplaceable core upstream capability provider for domestic high-end equipment.
Against the backdrop of continuous upgrades in domestic high-end medical equipment, the number of suppliers who can simultaneously provide component performance, rapid response, and mass production stability remains limited. If the platform further completes more medical terminal project targetings, its value will be reflected not only in manufacturing capability but also in long-term stickiness once it enters the core position of equipment architecture.

3. Heart Failure AAV Gene Therapy Platform

Project Focusing on heart failure, a major chronic disease scenario with a long-standing lack of breakthrough therapies, a gene therapy platform using AAV as the delivery platform has been established. Its core goal is to deliver long-term, Heart-directed expression improves key pathological mechanisms such as myocardial contraction, calcium signaling imbalance, inflammation, and myocardial remodeling. The platform is not a single pipeline, but a multi-project layout based on over twenty years of research on cardiac Ca2+ signaling and β-adrenergic signaling. Currently, it has multiple product lines including TO101, TO102, TO103, and TO104, covering indications such as heart failure after myocardial infarction, hypertrophy and heart failure caused by hypertension, right heart failure due to pulmonary hypertension, early cardiac dysfunction after myocardial infarction, and generalized heart failure. The leading pipeline TO101 uses an AAV9 vector and focuses on multiple mechanisms such as inhibiting PKA, CaMKII, inflammation, and enhancing ANP/BNP. It has shown potential in animal studies over β receptor blockers and has completed pilot process development, achieving high levels of total yield and unit yield at 50L fermentation.
The core appeal of these assets is not only the large market capacity of heart failure, but also the platform’s attempt to address the underlying mechanisms of disease rather than just symptom control. Although existing heart failure drugs can improve some indicators, their impact on five-year survival rates and recurrent hospitalizations is limited. If gene therapy can achieve long-term stable expression and precise organ delivery, it could change the long-term management model for chronic diseases. The platform emphasizes the safety and long-term effectiveness of AAV delivery, as well as a dual insurance design of “targeted expression + reduced off-target,” with potential to extend to a broader range of cardiovascular and cerebrovascular chronic disease scenarios. The team is also strong, including academic leaders with long-term research on heart failure mechanisms and gene therapy, as well as members with clinical development, toxicology, and Sino-US application experience from multinational pharmaceutical companies, providing comprehensive execution capabilities for the advancement of IND. For capital and industry sides, this is a CGT asset centered on heart failure, combining original mechanisms, delivery platform attributes, and multiple pipeline extension spaces.
If the leading pipeline successfully enters the IND, the project will have the opportunity to become one of the few truly AAV gene therapy assets targeting major chronic disease indications. Unlike most small-market gene therapy projects focused on rare diseases, once heart failure products are successfully validated, their potential payment potential, cooperation scale, and subsequent pipeline replication capabilities will all be significantly amplified.

4. Blood perfusion devices and blood purification material platforms

The project focuses on domestic substitution and high-end upgrading of blood purification consumables, with a core platform-based medical device asset built around blood perfusion devices and underlying adsorption materials. The technology originates from the national “13th Five-Year Plan” major project “Development of highly selective adsorbents and devices for whole blood perfusion,” forming a complete chain from resin material design and adsorption performance optimization to device conversion and registration. Currently, the fastest-progressing hematoperfusion device for nephrology has obtained Class III medical device registration certificates, capable of simultaneously removing medium and large molecule toxins and protein-bound toxins, and possesses strong specificity for β2-microglobulin and protein-binding toxin indicators; Compared to similar products, its primary cross-linked resin raw materials have advantages in manufacturing costs and potential toxicity control. Another key focus of the platform is the blood perfusion device for liver failure, positioned as the world’s first non-sodium-type high-efficiency bilirubin removal product, capable of whole blood perfusion, and outperforming major domestic and international products in bilirubin and bile acid clearance rates.

The investment logic for these assets is that the products are no longer in the “laboratory stage,” but have entered the period of registration, implementation, and hospital scale-up. Hemoperfusion is a high-frequency treatment scenario for chronic and critical illnesses, with core customer groups including nephrology, blood purification centers, ICUs, and clinical departments related to artificial livers. Once they enter the hospital system, they tend to have strong repurchase attributes and continuous consumable procurement. The team behind the platform has long been deeply engaged in blood purification materials, combining university research accumulation, national project translation experience, and production introduction capabilities, enabling not only individual device registration but also the conditions to further expand into kidney failure, liver failure, and more complex blood purification scenarios. Externally, the platform not only undertakes import substitution and clinical upgrades for hospitals, but also has the potential to extend to higher-level applications such as artificial livers and portable artificial kidneys. For investors, this is a high-barrier device platform that has obtained Class III certification, has national special endorsements, clearly differentiated clinical performance, and sustained hospital-side demand.
Meanwhile, the kidney and liver failure product lines share the same underlying materials and manufacturing systems, helping to shorten the subsequent new product introduction cycle and improve production line utilization and registration efficiency. Once platform-based device assets complete in-hospital validation, they can often scale up through multi-product matrices rather than single SKUs, which is an important source of long-term commercial value.

5. Hereditary Eye Disease AAV Gene Therapy Platform

Project focuses on the highly unmet field of hereditary eye diseases, with its core asset being an AAV gene therapy product targeting BCD, which has become the world’s first clinically advanced therapy for the same indication. This product focuses on treating retinal pigment epithelial dysfunction and photoreceptor degeneration caused by pathogenic gene defects, aiming to delay or even reverse the decline in visual function. Currently, the product has completed dosing for over 70 patients, ranking at the forefront of similar global projects; Early and key clinical data showed that about half of the subjects in the low-dose group achieved optimal corrected vision improvement ≥15 letters on Day365, which is not just safety verification but a clear signal of efficacy in humans. Meanwhile, the product has obtained breakthrough therapy qualification in China and RMAT certification in the United States. Phase III in China was completed in April 2026, and Phase III in multiple countries has also received FDA approval, entering the critical scale-up stage before global registration.
The core value of these assets lies in their ability to surpass early scientific validation and begin to meet global tradable conditions. The platform team has long focused on ophthalmic gene therapy, with clinical research experience on hereditary retinopathy and GMP-grade AAV R&D and production capabilitiesThis means the project is not just a single product advancement, but also a reflection of the capabilities of the ophthalmic gene therapy platform. Although BCD is a rare disease, it has a clear course, clear diagnostic pathway, strong patient willingness to pay, and regulatory incentives, making it more suitable for forming high value-added regional authorization and global cooperation. The most noteworthy thing now is not the concept, but the timing: domestic late-stage clinical trials have been completed, and international Phase III is about to begin, meaning future value enhancement will mainly come from advancing registrations, overseas equity cooperation, and bringing in commercialization partners. For both industry and capital players, this is an ophthalmic gene therapy asset that simultaneously possesses a globally pioneering position, clinical efficacy signals, dual regulatory acceleration recognition, and international cooperation channels.
From a transaction perspective, the project currently possesses several key elements for rare disease assets: clarifying genetic mechanisms, quantifiable clinical endpoints, rapid registration pathways, and global collaboration opportunities. With the launch of international multicenter trials, valuation support will come more from late-stage clinical advancement and regional equity spillovers, rather than just conceptual platform narratives.

This issue covers five major projects, covering four major areas: cell therapy, gene therapy, core components of medical devices, and blood purification consumables. All projects have entered clinical or IND stages. Investors and industry partners are welcome to discuss cooperation.

Cooperation and matchmaking channels !!!

If you are an investment institution, a listed pharmaceutical or device company, an overseas BD team, or an industry partner interested in the above projects, please scan the QR code below to add us on WeChat and seize innovation opportunities in the healthcare field together!

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.